EUVIMEDEUVIMED entdecken
Vergleichsstudie

Initial non-curative treatment for favorable intermediate-risk prostate cancer

Yuanming Chen, Xun Shangguan

International Urology and Nephrology · 2025

DOI: 10.1007/s11255-025-04768-9 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift International Urology and Nephrology, 2025. Verfasst von Yuanming Chen und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms. Die Arbeit nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To compare the oncologic outcomes of intermediate-risk prostate cancer (FIR-PCa) patients receiving different initial treatment regimens as more FIR-PCa patients are now recommended for non-radical treatment due to the side effects of radical therapy. METHODS: 8616 FIR prostate cancer patients were retrospectively evaluated using the Surveillance, Epidemiology, and End Results (SEER) database (2010-2015) and reported prostate cancer-specific survival (PCSS) for groups defined by the initial treatment category. Statistical analysis was performed using Pearson's chi-square test, Multivariate Cox proportional hazard regression, and Kaplan-Meier method. RESULTS: Kaplan-Meier curves of PCSS revealed that non-curative treatment provided worse disease control than curative management for FIR-PCa patients (Hazard ratio 5.9061; 95% confidence interval 3.3398-10.4446; p < 0.0001). After adjusting for age at diagnosis, race, T stage, PSA level, and Gleason score, non-curative management was significantly associated with a decrease in PCSS (Adjusted hazard ratio 3.34; 95% CI 1.97-5.67; p = 0.0027). CONCLUSION: Pending prospective validation, our findings do not support a 'uniform' increment in current utilization practices for non-curative treatment strategies for FIR-PCa.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsHumansMaleRetrospective StudiesAgedMiddle AgedSEER ProgramNeoplasm GradingKaplan-Meier EstimateProstatectomyNeoplasm StagingRisk AssessmentProportional Hazards ModelsProstate-Specific AntigenSurvival Rate

Stichwörter der Autor:innen

Curative managementEnd ResultsEpidemiologyFavorable intermediate-risk prostate cancerNon-curative treatmentSurveillance

Substanzen

Prostate-Specific Antigen

Autor:innen und Institutionen

  • Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, China.
  • Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, China. xun.shangguan@shgh.cn.

Zitieren

APA

Chen, Y., & Shangguan, X. (2025). Initial non-curative treatment for favorable intermediate-risk prostate cancer. International Urology and Nephrology. https://doi.org/10.1007/s11255-025-04768-9

Vancouver

Chen Y, Shangguan X. Initial non-curative treatment for favorable intermediate-risk prostate cancer. International Urology and Nephrology. 2025. doi:10.1007/s11255-025-04768-9

BibTeX
@article{Chen2025,
  author = {Chen, Yuanming and Shangguan, Xun},
  title = {Initial non-curative treatment for favorable intermediate-risk prostate cancer},
  journal = {International Urology and Nephrology},
  year = {2025},
  doi = {10.1007/s11255-025-04768-9}
}
Kostenlos starten →